Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 42 studies | 40% ± 14% | |
capillary endothelial cell | 14 studies | 31% ± 13% | |
endothelial cell of artery | 14 studies | 44% ± 15% | |
vein endothelial cell | 13 studies | 42% ± 17% | |
fibroblast | 10 studies | 24% ± 5% | |
type I pneumocyte | 9 studies | 28% ± 8% | |
retinal cone cell | 7 studies | 56% ± 10% | |
endothelial cell of vascular tree | 7 studies | 37% ± 15% | |
pericyte | 6 studies | 24% ± 8% | |
mesothelial cell | 6 studies | 43% ± 16% | |
glomerular endothelial cell | 4 studies | 43% ± 4% | |
cardiac muscle cell | 4 studies | 22% ± 4% | |
astrocyte | 4 studies | 29% ± 7% | |
natural killer cell | 4 studies | 19% ± 3% | |
oligodendrocyte | 4 studies | 22% ± 4% | |
microglial cell | 3 studies | 17% ± 1% | |
endocardial cell | 3 studies | 35% ± 6% | |
retinal rod cell | 3 studies | 27% ± 5% | |
mast cell | 3 studies | 24% ± 6% | |
endothelial cell of lymphatic vessel | 3 studies | 20% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
eye | 5 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 13518.11 | 653 / 653 | 96% | 97.69 | 580 / 605 |
breast | 100% | 7231.36 | 457 / 459 | 95% | 32.94 | 1061 / 1118 |
lung | 100% | 13800.56 | 578 / 578 | 92% | 28.35 | 1061 / 1155 |
esophagus | 96% | 4727.80 | 1392 / 1445 | 92% | 33.70 | 169 / 183 |
uterus | 100% | 5450.11 | 170 / 170 | 82% | 24.24 | 376 / 459 |
pancreas | 88% | 2553.27 | 287 / 328 | 93% | 30.12 | 166 / 178 |
kidney | 94% | 3380.60 | 84 / 89 | 83% | 38.40 | 752 / 901 |
prostate | 96% | 3870.60 | 236 / 245 | 81% | 15.47 | 408 / 502 |
adrenal gland | 98% | 3966.43 | 252 / 258 | 76% | 14.17 | 174 / 230 |
ovary | 94% | 3307.06 | 170 / 180 | 79% | 20.28 | 338 / 430 |
brain | 74% | 2071.17 | 1963 / 2642 | 98% | 28.05 | 691 / 705 |
bladder | 100% | 4239.67 | 21 / 21 | 67% | 15.40 | 339 / 504 |
intestine | 97% | 4895.66 | 937 / 966 | 69% | 15.12 | 365 / 527 |
skin | 80% | 7430.13 | 1447 / 1809 | 82% | 17.99 | 389 / 472 |
stomach | 84% | 3028.57 | 300 / 359 | 78% | 22.07 | 224 / 286 |
adipose | 100% | 10980.62 | 1204 / 1204 | 0% | 0 | 0 / 0 |
heart | 100% | 9324.42 | 858 / 861 | 0% | 0 | 0 / 0 |
spleen | 100% | 3601.49 | 240 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 6625.95 | 1324 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 15.40 | 25 / 29 |
tonsil | 0% | 0 | 0 / 0 | 82% | 21.06 | 37 / 45 |
muscle | 57% | 1161.97 | 459 / 803 | 0% | 0 | 0 / 0 |
liver | 9% | 202.86 | 21 / 226 | 47% | 8.12 | 190 / 406 |
peripheral blood | 26% | 1681.35 | 244 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 10% | 1.17 | 8 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0035024 | Biological process | negative regulation of Rho protein signal transduction |
GO_0030324 | Biological process | lung development |
GO_0009791 | Biological process | post-embryonic development |
GO_0001701 | Biological process | in utero embryonic development |
GO_0055017 | Biological process | cardiac muscle tissue growth |
GO_0060039 | Biological process | pericardium development |
GO_0007507 | Biological process | heart development |
GO_0035264 | Biological process | multicellular organism growth |
GO_0001570 | Biological process | vasculogenesis |
GO_1902414 | Biological process | protein localization to cell junction |
GO_0090271 | Biological process | positive regulation of fibroblast growth factor production |
GO_0003281 | Biological process | ventricular septum development |
GO_0045216 | Biological process | cell-cell junction organization |
GO_0003017 | Biological process | lymph circulation |
GO_0003209 | Biological process | cardiac atrium morphogenesis |
GO_0050878 | Biological process | regulation of body fluid levels |
GO_0001886 | Biological process | endothelial cell morphogenesis |
GO_0001945 | Biological process | lymph vessel development |
GO_0003222 | Biological process | ventricular trabecula myocardium morphogenesis |
GO_0048845 | Biological process | venous blood vessel morphogenesis |
GO_1905709 | Biological process | negative regulation of membrane permeability |
GO_2000299 | Biological process | negative regulation of Rho-dependent protein serine/threonine kinase activity |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0005911 | Cellular component | cell-cell junction |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | HEG1 |
Protein name | Protein HEG homolog 1 Heart development protein with EGF like domains 1 Alternative protein HEG1 |
Synonyms | KIAA1237 |
Description | FUNCTION: Receptor component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity. May act through the stabilization of endothelial cell junctions. . |
Accessions | ENST00000650592.2 Q9ULI3 A0A994J6K3 ENST00000311127.9 [Q9ULI3-1] L8ECI8 H7C4K2 ENST00000482699.1 |